Paysign Q2 2024 revenue up 29.8% to $14.33M; raises full-year guidance

Paysign, Inc.

2024-Q2 EPS reported $0.02 revenue$27,521,673

Net income of $697K ($0.01 diluted EPS) vs net loss of $104K in Q2 2023.
Adjusted EBITDA $2.24M, up 95.8% YoY; plasma revenue +12.6%, pharma patient affordability revenue +266.8%.
Added 8 net new plasma centers (477 total) and 8 net new patient affordability programs (61 total) in Q2.
FY 2024 revenue guidance raised to $56.5-$58.5M; adjusted EBITDA guided $9.0-$10.0M (15-17% of revenue).
Exited quarter with $31.29M unrestricted cash and zero debt.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.